Blackrock Neurotech is a leading developer of implantable brain-computer interface (BCI) technology, best known for the Utah Array — the most widely used invasive neural electrode array in clinical research. Founded in 2008 and headquartered in Salt Lake City, Utah, Blackrock has established itself as a pioneer in high-density electrophysiology recording and stimulation systems for neurological applications.
¶ Overview
Blackrock Neurotech — Brain-Computer Interface is a therapeutic candidate being investigated for the treatment of neurodegenerative diseases. This page provides comprehensive information on its mechanism of action, clinical development status, and therapeutic potential.
¶ Technology Platform
¶ Utah Array
The Utah Array is a silicon-based microelectrode array designed for chronic implantation in the motor cortex and other brain regions. Key characteristics include[1]:
- 96 recording sites arranged in a 10×10 grid (with center electrode removed)
- 1.5 mm electrode length (standard) — penetrates cortical layers
- Bio-compatible coating — parylene-C insulation
- Chronic stability — demonstrated functional for 10+ years in humans
- High signal quality — single-unit action potential recording
¶ Blackrock MicroPort
The next-generation Blackrock MicroPort represents an evolution of the Utah Array platform with improved characteristics[2]:
- Smaller footprint with higher electrode density
- Improved chronic reliability
- Higher spatial resolution for fine-grained neural decoding
- Compatible with the Utah Slant Array (variant with staggered electrode lengths)
¶ Neural Processing Pipeline
Blackrock systems integrate sophisticated signal processing:
- Signal Acquisition — Amplification, filtering, digitization
- Spike Sorting — Isolation of individual neuron activity
- Feature Extraction — Population firing rates, LFP spectral features
- Decoding Algorithms — Kalman filters, neural networks for movement prediction
¶ Clinical Applications
¶ BrainGate Clinical Trial
Blackrock technology powers the landmark BrainGate clinical trial — one of the most advanced BCI human studies[3][4]:
- Trial ID: NCT00912041
- Participants: Individuals with tetraplegia due to spinal cord injury or brainstem stroke
- Results:
- Cursor control with thought alone
- Click-through with >90% accuracy
- Robotic arm control for self-feeding
- Typing speeds up to 8 words/minute
¶ Amyotrophic Lateral Sclerosis (ALS)
Blackrock BCIs offer significant potential for ALS patients[5]:
- Communication restoration in locked-in state
- Environmental control (smart home integration)
- Respiratory monitoring and alert systems
¶ Parkinson's Disease
Parkinson's Disease research applications include[6]:
- Adaptive deep brain stimulation systems
- Tremor prediction algorithms
- Closed-loop therapeutic interventions
- Potential for neuroprotective interventions
¶ Competitive Landscape
| Feature | Blackrock Utah Array | Neuralink N1 | Synchron Stentrode |
|---|---|---|---|
| Invasiveness | Highly invasive (craniotomy) | Minimally invasive (craniotomy) | Minimally invasive (endovascular) |
| Electrode Count | 96-128 | 1,024 | 16 |
| Bandwidth | High | Very high | Moderate |
| Clinical Status | FDA IDE approved | FDA IDE approved | FDA IDE approved |
| Chronic Use | 10+ years |  years |
<2 years |
| Applications | ALS, PD, BCI | ALS, PD, tetraplegia | Stroke, ALS |
¶ Regulatory Status
- FDA Investigational Device Exemption (IDE): Approved for chronic implantation
- Breakthrough Device Designation: Granted for communication restoration in locked-in patients
- Humanitarian Use Device (HUD): Approved for specific neurological indications
¶ Research Partnerships
Blackrock collaborates with leading institutions:
- University of Utah — Signal processing and decoding algorithms](/institutions)
- Massachusetts General Hospital — BrainGate clinical trial](/institutions)
- Stanford University — Motor cortex neurophysiology](/institutions)
- Caltech — Neural decoding and prosthetics
¶ Advantages and Limitations
¶ Advantages
- Proven chronic stability — Longest track record of any implantable BCI
- High spatial resolution — Single-unit recording capability
- Regulatory pathway — Existing FDA IDE framework
- Research infrastructure — Established protocols and training programs
¶ Limitations
- Surgical risk — Requires craniotomy with associated morbidity
- Biocompatibility concerns — Glial scarring over time may reduce signal quality
- Limited scalability — 96-128 channels vs. Neuralink's 1,000+
- Cost — Device and surgery expenses exceeding $500,000
¶ Future Directions
Blackrock's development pipeline includes[7]:
- High-density arrays — Increasing electrode count to 1,000+ channels
- Wireless systems — Eliminating percutaneous connections
- Fully implantable — Integrated electronics and wireless telemetry
- Closed-loop systems — Real-time adaptive stimulation for therapeutic applications
¶ See Also
¶ References
¶ Additional references
Blackrock Neurotech. Utah Array Technical Specifications. ↩︎
Blackrock Neurotech. MicroPort Next-Generation Array. ↩︎
Willett FR, et al. Neural decoding of hand kinematics for neuroprosthetic control. Nat Commun. 2021. ↩︎
Hochberg LR, et al. Reach and grasp by people with tetraplegia using a neurally controlled robotic arm. Nature. 2012. ↩︎
Woolsey A, et al. Brain-computer interface for ALS communication. J Clin Neurol. 2021. ↩︎
Little S, et al. Adaptive deep brain stimulation for Parkinson's disease. Neurology. 2013. ↩︎
Blackrock Neurotech. Development Pipeline and Future Directions. ↩︎